SAB Biotherapeutics, Inc.
- SABS
- NASDAQ
- Biotechnology
- Immunotherapeutics
- Polyclonal Antibodies
- Clinical-Stage Biopharma
$2.60
Today +2.77%Quote Oct 19, 2026, 08:00 PM UTC
−27.71%over the last month
Max drawdown −29.1%From 1-month high −27.9%3 months −27.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
86
Founded
2014
Market value
$236.6M
Quote Oct 19
Floor
$2.51
3.6% below price
Resistance
$2.74
5.5% above price
Price vs analyst targets
8 analysts
Lowest target
$10.00Highest target
$13.00
$10.00Highest target
$13.00
- Price $2.60
- Average target $11.33
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 336% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SABSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free